Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Maryland MedicaidMedicaid · Reimbursement · Claims & Billing · MD · Psychiatry, Family Medicine, Internal MedicineMedium impact

PT 75-26: Updates to Reimbursement Rates and Coverage for Long-Acting Injectable Buprenorphine for Substance Use Disorders

Act
immediately
Effective date
Mar 1, 2026
Identified
Jun 18, 2026

Summary

Maryland Medicaid expanded coverage of long-acting injectable buprenorphine (Brixadi and Sublocade) to include nurse practitioners and physician assistants, and updated reimbursement rates for these substance use disorder treatments. Providers must purchase drugs directly from manufacturer and have current DEA registration to bill these codes.

Get alerts when payers change rules like this one

We check Maryland Medicaid and other payers every day and email you when a change matches your specialty and state.

Get Maryland Medicaid alertsPolicy Monitoring is free. No card required.

What to do

immediately · 3 steps
01Billing team must update system to include new reimbursement rates for buprenorphine injection codes J0577 ($420.05), J0578 ($1,680.21), Q9991/Q9992 ($1,998.53 each), and J2315 ($4.24/unit).
02Verify providers have current DEA registration in ePREP system.
03Only bill these codes when drug is purchased directly from manufacturer and administered in-office, not for pharmacy dispensing.

Codes mentioned

J0577J0578Q9991Q9992J2315

Original notice

PT 75-26: Updates to Reimbursement Rates and Coverage for Long-Acting Injectable Buprenorphine for Substance Use Disorders
health.maryland.gov · Always check the source before changing claims.
View original ↗

Related changes

See all Maryland Medicaid changes →
Updates to Reimbursement Rates and Coverage for Long-Acting Injectable Buprenorphine for Substance Use DisordersHighEffective Mar 1, 2026 · Behavioral Health Administration Services OrganizationCoverage of Buprenorphine Injection –REVISED May 13, 2020MediumEffective Jul 1, 2019 · Provider TransmittalCoverage of Brixadi for Opioid Use DisordersHighEffective Jan 1, 2025 · Behavioral Health Administration Services OrganizationUpdated Coverage of Brixadi for Opioid Use DisordersHighEffective Jan 1, 2025 · Behavioral Health Administration Services OrganizationBrowse every Maryland Medicaid change in the policy list

Related policy hubs

Maryland Medicaid policiesMD policy changesPsychiatryFamily MedicineInternal MedicineCode J0577Code J0578Code Q9991Code Q9992Code J2315

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account